Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAYBREAK: Setmelanotide in MC4R Pathway Genetic Obesity
NCT04963231Phase 2Completed
- Sponsor
- Rhythm Pharmaceuticals
- Start
- Nov 2021
- Primary completion
- Aug 2023
- Modality
- Peptides, Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of setmelanotide in Genetic obesity, sponsored by Rhythm Pharmaceuticals. Started Nov 2021; status: completed.
02
Drugs
setmelanotide
03
Conditions
Genetic obesity
Beyond the preview
Go deeper on NCT04963231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04963231.